Frontiers in Pharmacology (May 2024)

Effects of plant protease inhibitors (Pep-3-EcTI, Pep-BbKI, and Pep-BrTI) versus corticosteroids on inflammation, remodeling, and oxidative stress in an asthma–COPD (ACO) model

  • Juliana Morelli Lopes Gonçalves João,
  • Jéssica Anastácia Silva Barbosa,
  • Luana Laura Sales da Silva,
  • Silvia Fukuzaki,
  • Elaine Cristina de Campos,
  • Leandro do Nascimento Camargo,
  • Tabata Maruyama dos Santos,
  • Suellen Karoline Moreira Bezerra,
  • Francine Maria de Almeida,
  • Beatriz Mangueira Saraiva-Romanholo,
  • Beatriz Mangueira Saraiva-Romanholo,
  • Fernanda Degobbi Tenorio Quirino dos Santos Lopes,
  • Camila Ramalho Bonturi,
  • Renato Fraga Righetti,
  • Renato Fraga Righetti,
  • Maria Luiza Vilela Oliva,
  • Iolanda de Fátima Lopes Calvo Tibério,
  • Edna Aparecida Leick

DOI
https://doi.org/10.3389/fphar.2024.1282870
Journal volume & issue
Vol. 15

Abstract

Read online

The peptide derived from E. contortisiliquum trypsin inhibitor (Pep-3-EcTI), peptide derived from kallikrein inhibitor isolated from B. bauhinioides (Pep-BbKI), and B. rufa peptide modified from B. bauhinioides (Pep-BrTI) peptides exhibit anti-inflammatory and antioxidant activities, suggesting their potential for treating asthma–chronic obstructive pulmonary disease (COPD) overlap (ACO). We compared the effects of these peptides with dexamethasone (DX) treatment in an ACO model. In this study, 11 groups of male BALB/c mice were pre-treated under different conditions, including sensitization with intraperitoneal injection and inhalation of ovalbumin (OVA), intratracheal instillation of porcine pancreatic elastase (ELA), sensitization with intraperitoneal injection, and various combinations of peptide treatments with Pep-3-EcTI, Pep-BbKI, Pep-BrTI, dexamethasone, and non-treated controls (SAL-saline). Respiratory system resistance, airway resistance, lung tissue resistance, exhaled nitric oxide, linear mean intercept, immune cell counts in the bronchoalveolar lavage fluid, cytokine expression, extracellular matrix remodeling, and oxidative stress in the airways and alveolar septa were evaluated on day 28. Results showed increased respiratory parameters, inflammatory markers, and tissue remodeling in the ACO group compared to controls. Treatment with the peptides or DX attenuated or reversed these responses, with the peptides showing effectiveness in controlling hyperresponsiveness, inflammation, remodeling, and oxidative stress markers. These peptides demonstrated an efficacy comparable to that of corticosteroids in the ACO model. However, this study highlights the need for further research to assess their safety, mechanisms of action, and potential translation to clinical studies before considering these peptides for human use.

Keywords